Galectin Therapeutics Stock
Galectin Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Joel Lewis
- Employees
- 9
- Market cap
- $238 M
- IPO
- 04/09/2002
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3,…
Galectin Therapeutics stock: price history
1D
-2.4%
1W
-8.1%
1M
-1.6%
6M
+47.8%
YTD
-13.0%
1Y
-28.3%
2Y
+37.6%
5Y
+7.4%
10Y
+311.4%
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~17% weaker price swings than usual
Galectin Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 06/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Galectin Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics. The company's primary focus is on treating fibrotic diseases such as liver scarring associated with NASH cirrhosis as well as various cancers. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor currently in Phase III clinical trials. Additionally, the company is researching the development of orally bioavailable small molecules that block galectin-3 through a joint venture with SBH Sciences, Inc.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Galectin Therapeutics
Analyst assessment of Galectin Therapeutics
PRICE TARGET LOW
US$11.00
CONSENSUS
US$11.00
MEDIAN
US$11.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
9
BUY
2
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 23/06/2026
Galectin Therapeutics stock metrics
P/E
-8.48
P/B
-1.74
EV/EBITDA
-26.38
RETURN ON EQUITY
6.7%
NET MARGIN
0.0%
DEBT/EQUITY
-1.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.3%
FLOAT SHARES
46,933,907
AVG. DAILY VOLUME (30D)
275,335
Insider transactions (SEC)
Uihlein Richard E
Uihlein Richard E
Jamil Khurram
Jamil Khurram
Jamil Khurram
Attention
Price since yesterday: -2.4%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Galectin Therapeutics stock
What does Galectin Therapeutics do?
Galectin Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Joel Lewis, the company employs around 9 people.
The IPO was on 04/09/2002; the stock trades on NASDAQ under the ticker GALT.
What do analysts say about Galectin Therapeutics stock?
11 analysts rate the stock, the consensus is Buy (as of 23/06/2026).
The average price target is US$11.00, ranging from US$11.00 to US$11.00, with a median of US$11.00.
This is an external assessment, not a statement by Market Jury.
When does Galectin Therapeutics report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -17% stronger than usual.
Does Galectin Therapeutics pay a dividend?
No, Galectin Therapeutics currently does not pay a dividend.
Which stocks are comparable to Galectin Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Galectin Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Galectin Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.